While PSMA and DOTATATE bind specific receptors on the tumor itself (thus being theoretically more specific as they only bind to tumors with that receptor), FAP-targeted agents respond to the tumor microenvironment and bind to the cancer-associated fibroblasts (CAFs) surrounding many tumors. Here, FOLH1 is linked to neoplasm.